Terray Therapeutics Appoints Lisa L. Decker, Ph.D., as Chief Business Officer
Ms. Decker brings deep expertise in building high-impact biotech partnerships to Terray
Terray Therapeutics (www.terraytx.ai) announced today the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer. With 20+ years of biotechnology leadership and business development experience, Ms. Decker will lead the company’s business development strategy as Terray capitalizes on the multiple opportunities enabled by its industry-leading drug discovery platform, EMMI. EMMI combines precise, proprietary data at scale with full-stack AI to rapidly identify and optimize structurally novel medicines.
“Since our founding, we’ve known that AI could transform drug discovery, and now we’re realizing that vision. EMMI is affording us a rich internal pipeline that should enable us to enter the clinic multiple times in the coming years and is delivering for our pharma partners on their programs,” said Jacob Berlin, CEO. “Lisa will be an incredible asset and catalyst for our next stage as we evaluate opportunities for our medicines and continue to expand the impact of our platform across the pharma ecosystem. She brings together sophisticated business and science acumen alongside a mission-driven approach to building successful partnerships. I’m thrilled to have her on board.”
